India's two-tier manufacturing market identified; increased acquisitions predicted

A two-tier manufacturing market and forecast increased acquisitions by Indian companies, along with a notable improvement in the international reputation of Indian made pharmaceuticals have been identified in a new report for CPhI titled: 2017 India Pharma Market Report.

But perhaps most dramatically, a large majority of domestic companies called for urgent government support to invest in active pharmaceutical ingredient (API) sites.

The report, which consolidated opinions from 500 domestic and international companies, identified four main areas Indian pharma companies are investing in –  with 50% raising funds this year for ‘commercial scale and scale-up facilities,’ around one third for ‘continuous processing,’ and just over 20% each in both ‘biologics’ and ‘aseptic/sterile.’ Over the next three-years, however, the number of companies planning to invest in biomanufacturing facilities rises to one third. It’s notable that the more expensive facilities and capabilities needed for continuous processing and biomanufacturing are being added to India’s traditional base of commercial-scale finished-product facilities.